Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Vandana Singh

4606 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Top Stories

Citius Pharma’s ‘Antibiotic Lock’ Effective In Patients With Catheter-Associated Bloodstream Infections

By Vandana Singh
May 21, 1:40 PM
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall treatment success.

CTXR

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News
  • Top Stories

GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims

By Vandana Singh
May 21, 12:48 PM
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen, prompting a whistleblower lawsuit seeking billions in damages.

GSK

Read More
1 minute read
  • General
  • Health Care
  • Insurance
  • Large Cap
  • News
  • Top Stories

UnitedHealth’s OptumRx Unveils New Transparent Drug Pricing Initiative for 2024

By Vandana Singh
May 21, 10:54 AM
UnitedHealth's OptumRx will implement a new pricing model, OptumRx Clear Trend Guarantee, starting next year.

CAH

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide

By Vandana Singh
May 21, 9:36 AM
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 agonists are poised to drive a $2 billion market by 2030.

LLY

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

GSK’s Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows

By Vandana Singh
May 21, 8:31 AM
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.

GSK

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development

By Vandana Singh
May 21, 8:24 AM
Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma lifecycle.

MRNA

Read More
2 minute read
  • Biotech
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Top Stories

AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion

By Vandana Singh
May 21, 7:16 AM
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new medicines.

AZN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Top Stories

Why Is Dyne Therapeutics Stock Soaring On Monday?

By Vandana Singh
May 20, 3:53 PM
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle strength, and dystrophin expression were observed.

DYN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population

By Vandana Singh
May 20, 2:38 PM
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with higher blood eosinophil counts.

AMGN

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study

By Vandana Singh
May 20, 2:22 PM
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse events, a New Drug Application is planned for late 2024.

ESPR

Posts pagination

Previous 1 … 15 16 17 … 461 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service